PCI Biotech Holding ASA
PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development of technologies and novel therapies through its photochemical technology platform. The company's technology platform consists of a proprietary small molecule photosensitiser and a light source; and develops photochemical lysis (PCL) comprising light-triggered cell lysis, which enhances yield and purity in viral vecto… Read more
PCI Biotech Holding ASA - Asset Resilience Ratio
PCI Biotech Holding ASA (PCIB) has an Asset Resilience Ratio of 73.51% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2008–2024)
This chart shows how PCI Biotech Holding ASA's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down PCI Biotech Holding ASA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Nkr13.62 Million | 73.51% |
| Short-term Investments | Nkr0.00 | 0% |
| Total Liquid Assets | Nkr13.62 Million | 73.51% |
Asset Resilience Insights
- Very High Liquidity: PCI Biotech Holding ASA maintains exceptional liquid asset reserves at 73.51% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
PCI Biotech Holding ASA Industry Peers by Asset Resilience Ratio
Compare PCI Biotech Holding ASA's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
ESSA Pharma Inc
NASDAQ:EPIX |
Biotechnology | 21.42% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for PCI Biotech Holding ASA (2008–2024)
The table below shows the annual Asset Resilience Ratio data for PCI Biotech Holding ASA.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 86.72% | Nkr27.07 Million | Nkr31.21 Million | -6.78pp |
| 2023-12-31 | 93.49% | Nkr41.18 Million | Nkr44.05 Million | +4.34pp |
| 2022-12-31 | 89.15% | Nkr56.60 Million | Nkr63.48 Million | +3.76pp |
| 2021-12-31 | 85.39% | Nkr116.12 Million | Nkr135.98 Million | -4.49pp |
| 2020-12-31 | 89.88% | Nkr187.97 Million | Nkr209.12 Million | -2.70pp |
| 2019-12-31 | 92.58% | Nkr261.10 Million | Nkr282.03 Million | -5.26pp |
| 2018-12-31 | 97.84% | Nkr349.33 Million | Nkr357.06 Million | +10.92pp |
| 2017-12-31 | 86.91% | Nkr50.79 Million | Nkr58.44 Million | +24.40pp |
| 2016-12-31 | 62.51% | Nkr14.00 Million | Nkr22.40 Million | +61.59pp |
| 2013-12-31 | 0.93% | Nkr489.00K | Nkr52.74 Million | +0.34pp |
| 2012-12-31 | 0.59% | Nkr463.00K | Nkr78.20 Million | +0.24pp |
| 2011-12-31 | 0.35% | Nkr351.00K | Nkr100.17 Million | -91.21pp |
| 2010-12-31 | 91.56% | Nkr104.88 Million | Nkr114.54 Million | +10.65pp |
| 2009-12-31 | 80.91% | Nkr33.60 Million | Nkr41.53 Million | -7.86pp |
| 2008-12-31 | 88.77% | Nkr48.45 Million | Nkr54.58 Million | -- |